Starting in 2022, increased demand led to shortages of semaglutide injections sold by Novo Nordisk under the brand names Ozempic and Wegovy, as well as tirzepatide injections Zepbound and Mounjaro from competitor Eli Lilly
Real-world data suggests comparable weight loss outcomes between oral and injectable semaglutide when doses are optimized, though individual results vary more with oral formulations
Instead, it is FDA approved for managing Type 2 diabetes
This can mess up your digestion and lead to several problems, like feeling nauseous, throwing up (sometimes even food that hasnt been digested), belly pain, bloating, getting severely dehydrated, feeling full quickly when eating, food not digesting and staying in the stomach, acid reflux, blood sugar levels going up and down, not feeling hungry, losing weight, not getting enough nutrients, and a drop in your quality of life
Furthermore, oral administration is more prone to experiencing adverse events (AE) that are not listed in the product labeling
